title: [Breast cancer: radiotherapy and estrogen signaling].
abstract: Hormone receptors are expressed in more than 75% of breast cancer. Therefore, two prescription modalities of endocrine therapy could be proposed: either sequential or concomitant to breast cancer irradiation. If combined to radiotherapy, is endocrine therapy a radiosensitizer? Does endocrine therapy enhance the risk factor of radio-induced toxicity? Here, we will distinguish the interaction of ionizing radiation combined with therapies targeting oestrogen receptor (REα) from the interaction of ionizing radiation with oestrogen. This review aims at making clear all these items.
authors.affiliation: INSERM U896, Institut régional du cancer de Montpellier, Département de radiothérapie oncologique, 208 rue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 05, France.
authors.forename: Céline
authors.initials: C
authors.lastname: Bourgier
authors.affiliation: INSERM U896, Institut régional du cancer de Montpellier, Département de radiothérapie oncologique, 208 rue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 05, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Lemanski
authors.affiliation: ICM, Département d'oncologie médicale, Montpellier, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Romieu
authors.affiliation: Centre hospitalier universitaire Vaudois, Service d'oncologie médicale, Lausanne, 1011, Suisse.
authors.forename: Mahmut
authors.initials: M
authors.lastname: Ozsahin
authors.affiliation: INSERM U896, Institut régional du cancer de Montpellier, Département de radiothérapie oncologique, 208 rue des Apothicaires, Parc Euromédecine, 34298 Montpellier Cedex 05, France.
authors.forename: David
authors.initials: D
authors.lastname: Azria
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000378:metabolism* / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods*; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D004967:Estrogens / Q000378:metabolism*; D005260:Female; D000077267:Fulvestrant; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D017564:Radiation Pneumonitis / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000378:metabolism*; D015398:Signal Transduction; D013629:Tamoxifen / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D011960:Receptors, Estrogen; D013629:Tamoxifen; D000077267:Fulvestrant; D004958:Estradiol
keywords: adjuvant; breast cancer; concomitant; endocrine therapy; radiotherapy